Education
About Us
Working with TipRanks
Follow Us
Adaptive Biotechnologies (ADPT)
:ADPT
ADPT Analyst Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ADPT Stock 12 Month Forecast
Average Price Target
$13.75
▲(8.52% Upside)
| Highest Price Target$15.00 | Average Price Target$13.75 | Lowest Price Target$11.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
$14
Buy
10.50%
Upside
Reiterated
08/19/25
William Blair
―
Buy
―
Reiterated
08/18/25
Adaptive Biotechnologies: Strategic Flexibility and Innovation Drive Buy RatingWe take this announcement as a positive and reiterate our Outperform rating. While the agreement certainly had its benefits when signed (the upfront cash; external validation of platform), the collaboration struggled to meaningfully move forward in recent years and Adaptive could not control the pacing of or external discussion related to progress. We also believe nearly all investors had written off the potential for long-term milestones/royalties. With this termination, it releases Adaptive from exclusivity, which could enable Adaptive to partner with other parties interested in its library.
J.P. Morgan
―
Buy
―
Reiterated
08/18/25
TD Cowen
$13→$15
Buy
18.39%
Upside
Assigned
08/06/25
Piper Sandler
$13→$15
Buy
18.39%
Upside
Reiterated
08/06/25
Morgan Stanley
$9→$11
Hold
-13.18%
Downside
Reiterated
08/06/25
Craig-Hallum
―
Buy
―
Reiterated
08/04/25
Scotiabank
$12
Buy
-5.29%
Downside
Reiterated
05/05/25
Goldman Sachs
$8→$9
Buy
-28.97%
Downside
Upgraded
03/21/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
$14
Buy
10.50%
Upside
Reiterated
08/19/25
William Blair
―
Buy
―
Reiterated
08/18/25
Adaptive Biotechnologies: Strategic Flexibility and Innovation Drive Buy RatingWe take this announcement as a positive and reiterate our Outperform rating. While the agreement certainly had its benefits when signed (the upfront cash; external validation of platform), the collaboration struggled to meaningfully move forward in recent years and Adaptive could not control the pacing of or external discussion related to progress. We also believe nearly all investors had written off the potential for long-term milestones/royalties. With this termination, it releases Adaptive from exclusivity, which could enable Adaptive to partner with other parties interested in its library.
J.P. Morgan
―
Buy
―
Reiterated
08/18/25
TD Cowen
$13→$15
Buy
18.39%
Upside
Assigned
08/06/25
Piper Sandler
$13→$15
Buy
18.39%
Upside
Reiterated
08/06/25
Morgan Stanley
$9→$11
Hold
-13.18%
Downside
Reiterated
08/06/25
Craig-Hallum
―
Buy
―
Reiterated
08/04/25
Scotiabank
$12
Buy
-5.29%
Downside
Reiterated
05/05/25
Goldman Sachs
$8→$9
Buy
-28.97%
Downside
Upgraded
03/21/25
Best Analysts Covering Adaptive Biotechnologies
1 Month
xxx
Success Rate
9/18 ratings generated profit
Average Return
-0.88%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.88% per trade.
3 Months
xxx
Success Rate
8/11 ratings generated profit
Average Return
+7.09%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +7.09% per trade.
1 Year
Success Rate
9/11 ratings generated profit
Average Return
+72.68%
reiterated a buy rating 10 days ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +72.68% per trade.
2 Years
xxx
Success Rate
11/11 ratings generated profit
Average Return
+153.04%
reiterated a xxx
rating 10 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +153.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ADPT Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
11
13
12
11
12
Hold
5
8
10
12
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
21
22
23
24
Each month's total comprises the sum of three months' worth of ratings.
ADPT Financial Forecast
ADPT Stock Forecast FAQ
What is ADPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Adaptive Biotechnologies’s 12-month average price target is 13.75.
What is ADPT’s upside potential, based on the analysts’ average price target?
Adaptive Biotechnologies has 8.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ADPT a Buy, Sell or Hold?
Adaptive Biotechnologies has a consensus rating of Strong Buy which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
What is Adaptive Biotechnologies’s price target?
The average price target for Adaptive Biotechnologies is 13.75. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $11.00. The average price target represents 8.52% Increase from the current price of $12.67.
The highest analyst price target is $15.00 ,the lowest forecast is $11.00. The average price target represents 8.52% Increase from the current price of $12.67.
What do analysts say about Adaptive Biotechnologies?
Adaptive Biotechnologies’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of ADPT?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.